Elanco Animal Health Inc
F:5EA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.112
21.425
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Elanco Animal Health Inc
NYSE:ELAN
|
12.2B USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Zoetis Inc
NYSE:ZTS
|
54.8B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Elanco Animal Health Inc
Glance View
Elanco Animal Health Inc. emerged from the hallowed halls of Eli Lilly and Company, officially standing on its own in 2018, and immediately carving out its identity as a key player in animal health. The company, headquartered in Greenfield, Indiana, prides itself on working at the intersection of science and animal well-being, bringing innovative solutions to the market. Elanco's operations revolve around two primary business segments: Companion Animal and Farm Animal. In the Companion Animal segment, the focus is squarely on developing products that improve the health and extend the lives of pets, from flea and tick treatments to vaccines that safeguard them against disease. This segment taps into the growing humanization of pets, leveraging the emotional bond between owners and animals to drive demand for premium pet healthcare products. On the other hand, Elanco's Farm Animal segment is deeply woven into the fabric of the agricultural ecosystem, serving the needs of livestock operations around the globe. This division offers a suite of products that enhance the health and productivity of cattle, swine, poultry, and aqua species, addressing concerns from disease prevention to growth efficiency. By providing antibiotics, vaccines, and other nutritional health additives, Elanco helps farmers meet the world's growing demand for protein while complying with the ever-stringent regulations on animal product safety and efficacy. The company's diversified portfolio and its global reach allow it to monetize the vast and varied animal health landscape effectively, positioning itself as a stalwart in the sector dedicated not just to animal care but to elevating the industry standards through innovation and responsible growth.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Elanco Animal Health Inc is 55%, which is below its 3-year median of 55.8%.
Over the last 3 years, Elanco Animal Health Inc’s Gross Margin has decreased from 56.5% to 55%. During this period, it reached a low of 54.7% on Sep 30, 2024 and a high of 57.3% on Sep 30, 2023.